JP2018510132A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018510132A5 JP2018510132A5 JP2017540830A JP2017540830A JP2018510132A5 JP 2018510132 A5 JP2018510132 A5 JP 2018510132A5 JP 2017540830 A JP2017540830 A JP 2017540830A JP 2017540830 A JP2017540830 A JP 2017540830A JP 2018510132 A5 JP2018510132 A5 JP 2018510132A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- chain consists
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 6
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 3
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 230000003993 interaction Effects 0.000 claims 3
- 108010029697 CD40 Ligand Proteins 0.000 claims 1
- 102100032937 CD40 ligand Human genes 0.000 claims 1
- 229960003697 abatacept Drugs 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 229950001109 galiximab Drugs 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562111261P | 2015-02-03 | 2015-02-03 | |
| US62/111,261 | 2015-02-03 | ||
| PCT/US2016/016165 WO2016126702A1 (en) | 2015-02-03 | 2016-02-02 | Anti-cd40l antibodies and methods for treating cd40l-related diseases or disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020191310A Division JP2021054826A (ja) | 2015-02-03 | 2020-11-18 | Ｃｄ４０ｌ関連疾患または障害を治療するための抗ｃｄ４０ｌ抗体及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018510132A JP2018510132A (ja) | 2018-04-12 |
| JP2018510132A5 true JP2018510132A5 (OSRAM) | 2019-03-14 |
| JP6797810B2 JP6797810B2 (ja) | 2020-12-09 |
Family
ID=56564599
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017540830A Active JP6797810B2 (ja) | 2015-02-03 | 2016-02-02 | Ｃｄ４０ｌ関連疾患または障害を治療するための抗ｃｄ４０ｌ抗体及び方法 |
| JP2020191310A Withdrawn JP2021054826A (ja) | 2015-02-03 | 2020-11-18 | Ｃｄ４０ｌ関連疾患または障害を治療するための抗ｃｄ４０ｌ抗体及び方法 |
| JP2022199466A Pending JP2023036717A (ja) | 2015-02-03 | 2022-12-14 | Ｃｄ４０ｌ関連疾患または障害を治療するための抗ｃｄ４０ｌ抗体及び方法 |
| JP2025006366A Pending JP2025081304A (ja) | 2015-02-03 | 2025-01-16 | Ｃｄ４０ｌ関連疾患または障害を治療するための抗ｃｄ４０ｌ抗体及び方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020191310A Withdrawn JP2021054826A (ja) | 2015-02-03 | 2020-11-18 | Ｃｄ４０ｌ関連疾患または障害を治療するための抗ｃｄ４０ｌ抗体及び方法 |
| JP2022199466A Pending JP2023036717A (ja) | 2015-02-03 | 2022-12-14 | Ｃｄ４０ｌ関連疾患または障害を治療するための抗ｃｄ４０ｌ抗体及び方法 |
| JP2025006366A Pending JP2025081304A (ja) | 2015-02-03 | 2025-01-16 | Ｃｄ４０ｌ関連疾患または障害を治療するための抗ｃｄ４０ｌ抗体及び方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (6) | US10106618B2 (OSRAM) |
| EP (2) | EP3253412B1 (OSRAM) |
| JP (4) | JP6797810B2 (OSRAM) |
| KR (2) | KR102747565B1 (OSRAM) |
| CN (2) | CN108064168B (OSRAM) |
| AU (3) | AU2016215505B8 (OSRAM) |
| CA (1) | CA2974135A1 (OSRAM) |
| DK (1) | DK3253412T3 (OSRAM) |
| GB (1) | GB2552429A (OSRAM) |
| IL (3) | IL322241A (OSRAM) |
| MA (1) | MA41459A (OSRAM) |
| MX (2) | MX392480B (OSRAM) |
| RU (1) | RU2727646C2 (OSRAM) |
| SG (2) | SG10201912752QA (OSRAM) |
| WO (1) | WO2016126702A1 (OSRAM) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2683406T3 (pl) | 2011-03-11 | 2019-11-29 | Beth Israel Deaconess Medical Ct Inc | Przeciwciała anty-cd40 i ich zastosowania |
| MA41459A (fr) * | 2015-02-03 | 2017-12-12 | Als Therapy Development Inst | Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l |
| BR112018004296B1 (pt) | 2015-09-04 | 2020-05-05 | Primatope Therapeutics Inc | anticorpos anti-cd40 humanizados e usos dos mesmos |
| US11384152B2 (en) * | 2017-05-24 | 2022-07-12 | Als Therapy Development Institute | Therapeutic anti-CD40 ligand antibodies |
| SMT202400527T1 (it) * | 2019-07-01 | 2025-01-14 | Tonix Pharma Ltd | Anticorpi anti-cd154 e loro usi |
| WO2021006604A1 (ko) * | 2019-07-08 | 2021-01-14 | 주식회사 프로젠 | 신규 융합단백질 및 그의 용도 |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| EP4274587A1 (en) * | 2021-01-06 | 2023-11-15 | Tonix Pharma Limited | Methods of inducing immune tolerance with modified anti-cd154 antibodies |
| CA3209479A1 (en) | 2021-02-03 | 2022-08-11 | Mozart Therapeutics, Inc. | Binding agents and methods of using the same |
| WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
| US12234294B2 (en) | 2021-11-05 | 2025-02-25 | Kiniksa Pharmaceuticals, Gmbh | Pharmaceutical composition of a humanized anti-CD40 antibody |
| CN114149508B (zh) * | 2021-11-25 | 2023-04-28 | 苏州普乐康医药科技有限公司 | 一种结合cd40l的融合蛋白及其应用 |
| KR20230108156A (ko) * | 2022-01-10 | 2023-07-18 | 주식회사 금호에이치티 | Cd40l에 특이적으로 결합하는 항체 및 그의 용도 |
| WO2024211211A1 (en) | 2023-04-03 | 2024-10-10 | Regeneron Pharmaceuticals, Inc. | Methods of improving transplant survival using il-2 receptor gamma chain antibodies |
| WO2025117849A1 (en) | 2023-11-28 | 2025-06-05 | Eledon Pharmaceuticals, Inc. | Methods and compositions for prevention of transplant rejection |
| WO2025235683A1 (en) | 2024-05-07 | 2025-11-13 | Eledon Pharmaceuticals, Inc. | Methods and compositions for prevention of transplant rejection |
| WO2025235670A1 (en) | 2024-05-07 | 2025-11-13 | Eledon Pharmaceuticals, Inc. | Use of anti-cd40 ligand antibodies for immunosuppression in islet cell transplantation |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US5961974A (en) | 1991-10-25 | 1999-10-05 | Immunex Corporation | Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same |
| US5962406A (en) | 1991-10-25 | 1999-10-05 | Immunex Corporation | Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same |
| US7070777B1 (en) | 1991-11-15 | 2006-07-04 | The Trustees Of Columbia University In The City Of New York | Method for inhibiting inflammation with an antibody that binds the 5C8 protein |
| US5474771A (en) | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
| CA2089229C (en) | 1992-02-14 | 2010-04-13 | Alejandro A. Aruffo | Cd40cr receptor and ligands therefor |
| NZ273221A (en) | 1993-09-02 | 2001-09-28 | Dartmouth College | Pharmaceutical for inducing antigen-specific T cell tolerance |
| US5833987A (en) | 1995-06-07 | 1998-11-10 | Trustees Of Dartmouth College | Treatment of T cell mediated autoimmune disorders |
| US6001358A (en) | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
| US6340459B1 (en) | 1995-12-01 | 2002-01-22 | The Trustees Of Columbia University In The City Of New York | Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients |
| TR199902191T2 (xx) | 1997-01-10 | 1999-12-21 | Biogen, Inc. | Anti-CD40L bile�ikleri ile lupus nefritis tedavisi |
| EA002549B1 (ru) | 1997-05-17 | 2002-06-27 | Байоджен, Инк. | Применение блокатора связывания cd40:cd154 для предотвращения противоадаптивных иммунных реакций, в частности отторжения трансплантата |
| JP2002510643A (ja) | 1998-04-03 | 2002-04-09 | トラスティーズ・オブ・ダートマス・カレッジ | 狼瘡およびその関連腎臓疾患の治療および／または後退のための抗−ｇｐ３９抗体の使用 |
| US6946129B1 (en) | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
| EP1229935A1 (en) | 1999-11-08 | 2002-08-14 | Idec Pharmaceuticals Corporation | Treatment of b cell malignancies using anti-cd40l antibodies in combination with anti-cd20 antibodies and/or chemotherapeutics and radiotherapy |
| WO2001056603A1 (en) | 2000-02-01 | 2001-08-09 | Tanox, Inc. | Cd40-binding apc-activating molecules |
| GB0006398D0 (en) | 2000-03-16 | 2000-05-03 | Novartis Ag | Organic compounds |
| AU2001259215A1 (en) | 2000-04-28 | 2001-11-12 | La Jolla Institute For Allergy And Immunology | Human anti-cd40 antibodies and methods of making and using same |
| BR0110779A (pt) * | 2000-05-12 | 2005-01-11 | Beth Israel Hospital | Composições e métodos para adquirir supressão imunológica |
| AU6461201A (en) | 2000-07-12 | 2002-01-21 | Idec Pharma Corp | Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications |
| WO2002018540A2 (en) | 2000-09-01 | 2002-03-07 | Biogen, Inc. | Pyridine derivatives useful as cd40:cd154 binding interruptor compounds and use thereof to treat immunological complications |
| AU8867501A (en) | 2000-09-01 | 2002-03-13 | Biogen Inc | Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design |
| US20040110226A1 (en) * | 2002-03-01 | 2004-06-10 | Xencor | Antibody optimization |
| AU2003284968A1 (en) | 2002-10-25 | 2004-05-13 | University Of South Florida | Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease |
| NZ544486A (en) | 2003-06-13 | 2009-04-30 | Biogen Idec Inc | Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof |
| JP2007527703A (ja) | 2003-07-08 | 2007-10-04 | ジェネスト アー／エス | 肺炎球菌表面付着因子Ａタンパク質（ＰｓａＡ）に関する結合メンバー |
| NZ580688A (en) | 2003-07-26 | 2012-03-30 | Biogen Idec Inc | Method of designing altered antibodies having improved antigen-binding affinity |
| WO2005018572A2 (en) * | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Improved antibodies having altered effector function and methods for making the same |
| US20170166655A1 (en) | 2004-03-26 | 2017-06-15 | Xencor, Inc. | Novel immunoglobulin variants |
| JP5102028B2 (ja) | 2004-07-26 | 2012-12-19 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 抗ｃｄ１５４抗体 |
| US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| WO2006108035A1 (en) * | 2005-04-06 | 2006-10-12 | Bristol-Myers Squibb Company | Methods for treating immune disorders associated with graft transplantation with soluble ctla4 mutant molecules |
| WO2006138316A2 (en) | 2005-06-14 | 2006-12-28 | Biogen Idec Ma Inc. | Methods for delivering molecules to the central nervous system |
| KR100772247B1 (ko) | 2005-11-04 | 2007-11-01 | 엘지전자 주식회사 | 평면 디스플레이 기기 및 평면 디스플레이 기기의 냉각장치 |
| AU2006315274B2 (en) | 2005-11-17 | 2012-07-05 | Biogen Ma Inc. | Platelet aggregation assays |
| CN101584858A (zh) | 2005-12-20 | 2009-11-25 | 布里斯托尔-迈尔斯斯奎布公司 | 稳定蛋白质制剂 |
| US7647438B1 (en) * | 2006-05-09 | 2010-01-12 | Integrated Device Technology, Inc. | Binary base address sorting method and device with shift vector |
| WO2008140603A2 (en) | 2006-12-08 | 2008-11-20 | Macrogenics, Inc. | METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING |
| EP2125894B1 (en) | 2007-03-22 | 2018-12-19 | Biogen MA Inc. | Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof |
| CN101802197A (zh) | 2007-05-14 | 2010-08-11 | 比奥根艾迪克Ma公司 | 单链FC（ScFc）区、包含其的结合多肽及与其相关的方法 |
| JP5767109B2 (ja) | 2008-07-17 | 2015-08-19 | ノバルティス アーゲー | 治療抗体を用いる組成物及び方法 |
| GB0815788D0 (en) | 2008-08-29 | 2008-10-08 | Isis Innovation | Therapeutic antibodies |
| US9044459B2 (en) | 2008-12-05 | 2015-06-02 | Als Therapy Development Institute | Method for the treatment of neurodegenerative diseases |
| EP2367849B1 (en) * | 2008-12-05 | 2017-11-01 | ALS Therapy Development Institute | Method for the treatment of neurodegenerative diseases |
| CN102369291A (zh) * | 2009-01-23 | 2012-03-07 | 比奥根艾迪克Ma公司 | 效应子功能降低的稳定Fc多肽及使用方法 |
| US20120100166A1 (en) * | 2010-07-15 | 2012-04-26 | Zyngenia, Inc. | Ang-2 Binding Complexes and Uses Thereof |
| EP2625203A1 (en) | 2010-10-05 | 2013-08-14 | Novartis AG | Anti-il12rbeta1 antibodies and their use in treating autoimmune and inflammatory disorders |
| WO2012103218A1 (en) | 2011-01-25 | 2012-08-02 | University Of South Florida | A transgenic model of alzheimer's disease |
| HUE041335T2 (hu) | 2011-03-29 | 2019-05-28 | Roche Glycart Ag | Antitest FC-variánsok |
| CA2832281C (en) | 2011-04-04 | 2019-11-05 | Trustees Of Dartmouth College | Anti-cd154 antibodies having impaired fcr binding and/or complement binding properties and the use thereof in immune therapies |
| US9028826B2 (en) | 2011-04-04 | 2015-05-12 | The Trustees Of Dartmouth College | Methods of immune therapy with anti-CD154 antibodies having impaired FcR binding and/or complement binding properties |
| PL2699601T3 (pl) * | 2011-04-21 | 2018-05-30 | Bristol-Myers Squibb Company | Polipeptydy przeciwciała, które antagonizują CD40 |
| CA2843158A1 (en) | 2011-08-26 | 2013-03-07 | Merrimack Pharmaceuticals, Inc. | Tandem fc bispecific antibodies |
| TW201326209A (zh) * | 2011-09-30 | 2013-07-01 | Chugai Pharmaceutical Co Ltd | 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子 |
| SMT202000091T1 (it) * | 2011-10-13 | 2020-05-08 | Bristol Myers Squibb Co | Polipeptidi anticorpali che antagonizzano cd40l |
| KR20140099317A (ko) | 2011-12-08 | 2014-08-11 | 프리시플렉스 에스에이 | 부피가 작은 정밀 벨로즈 |
| SG10201609447XA (en) | 2012-05-11 | 2017-01-27 | Medimmune Llc | Ctla-4 variants |
| EP2909303B1 (en) | 2012-10-18 | 2020-04-15 | Yongxin Zhang | Bioreactor system and methods for alternative cell culture between static and dynamic |
| CA2908350C (en) * | 2013-04-02 | 2023-08-08 | Futa Mimoto | Fc region variant |
| WO2015035215A1 (en) * | 2013-09-05 | 2015-03-12 | Amgen Inc. | Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles |
| CN106132429A (zh) * | 2014-03-19 | 2016-11-16 | 百时美施贵宝公司 | 使用针对cd40l的域抗体治疗移植物排斥的方法 |
| EP3134109A1 (en) | 2014-04-25 | 2017-03-01 | Bristol-Myers Squibb Company | Use of ctla4 compound for achieving drug-free remission in subjects with early ra |
| WO2016028810A1 (en) | 2014-08-18 | 2016-02-25 | Biogen Ma Inc. | Anti-cd40 antibodies and uses thereof |
| MA41459A (fr) * | 2015-02-03 | 2017-12-12 | Als Therapy Development Inst | Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l |
| US11384152B2 (en) | 2017-05-24 | 2022-07-12 | Als Therapy Development Institute | Therapeutic anti-CD40 ligand antibodies |
-
2016
- 2016-02-01 MA MA041459A patent/MA41459A/fr unknown
- 2016-02-02 AU AU2016215505A patent/AU2016215505B8/en active Active
- 2016-02-02 CN CN201680008506.4A patent/CN108064168B/zh active Active
- 2016-02-02 CN CN202111202841.7A patent/CN114195895B/zh active Active
- 2016-02-02 MX MX2017009694A patent/MX392480B/es unknown
- 2016-02-02 KR KR1020177021029A patent/KR102747565B1/ko active Active
- 2016-02-02 CA CA2974135A patent/CA2974135A1/en active Pending
- 2016-02-02 EP EP16747111.9A patent/EP3253412B1/en active Active
- 2016-02-02 IL IL322241A patent/IL322241A/en unknown
- 2016-02-02 DK DK16747111.9T patent/DK3253412T3/da active
- 2016-02-02 EP EP22163613.7A patent/EP4071175A1/en active Pending
- 2016-02-02 RU RU2017126997A patent/RU2727646C2/ru active
- 2016-02-02 GB GB1713871.0A patent/GB2552429A/en not_active Withdrawn
- 2016-02-02 SG SG10201912752QA patent/SG10201912752QA/en unknown
- 2016-02-02 SG SG11201706258WA patent/SG11201706258WA/en unknown
- 2016-02-02 KR KR1020247042620A patent/KR20250007045A/ko active Pending
- 2016-02-02 JP JP2017540830A patent/JP6797810B2/ja active Active
- 2016-02-02 WO PCT/US2016/016165 patent/WO2016126702A1/en not_active Ceased
-
2017
- 2017-07-19 IL IL253571A patent/IL253571B/en unknown
- 2017-07-26 MX MX2022005655A patent/MX2022005655A/es unknown
- 2017-08-02 US US15/667,477 patent/US10106618B2/en active Active
-
2018
- 2018-09-07 US US16/125,317 patent/US10683356B2/en active Active
-
2020
- 2020-05-13 US US15/931,315 patent/US11014990B2/en active Active
- 2020-11-18 JP JP2020191310A patent/JP2021054826A/ja not_active Withdrawn
-
2021
- 2021-05-17 US US17/322,486 patent/US11692040B2/en active Active
- 2021-11-03 IL IL287823A patent/IL287823A/en unknown
-
2022
- 2022-01-19 AU AU2022200323A patent/AU2022200323B2/en active Active
- 2022-12-14 JP JP2022199466A patent/JP2023036717A/ja active Pending
-
2023
- 2023-06-26 US US18/341,202 patent/US12275793B2/en active Active
-
2024
- 2024-07-02 AU AU2024204572A patent/AU2024204572A1/en active Pending
-
2025
- 2025-01-16 JP JP2025006366A patent/JP2025081304A/ja active Pending
- 2025-01-17 US US19/030,443 patent/US20250263493A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018510132A5 (OSRAM) | ||
| JP2012136541A5 (OSRAM) | ||
| PE20241623A1 (es) | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos | |
| FI3389699T3 (fi) | Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja | |
| AR088455A1 (es) | Anticuerpos que antagonizan cd40l | |
| JP2011219478A5 (OSRAM) | ||
| HRP20210250T1 (hr) | Učinkovita i djelotvorna kontrola serumskog fosfata za optimalno stvaranje kostiju | |
| JP2019507180A5 (OSRAM) | ||
| JP2017503014A5 (OSRAM) | ||
| MX363226B (es) | Formulaciones de anticuerpos. | |
| JP2013517277A5 (OSRAM) | ||
| MX2012008999A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX340015B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX342291B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX340016B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| JP2010202664A5 (OSRAM) | ||
| JP2008538564A5 (OSRAM) | ||
| AR102593A1 (es) | Anticuerpos anti-pdgf-b y métodos de uso | |
| AR082629A1 (es) | Anticuerpos anti-fap (proteina de activacion fibroblastica) y metodos de uso | |
| NZ608502A (en) | Polypeptides that bind to human complement component c5 | |
| JP2012102122A5 (OSRAM) | ||
| JP2013172734A5 (OSRAM) | ||
| JP2013543505A5 (OSRAM) | ||
| HK1212253A1 (en) | Combinations of modalities for the treatment of diabetes | |
| EP4534107A3 (en) | Protein complex by use of a specific site of an immunoglobulin fragment for linkage |